Semax vs Selank: Two Russian Nootropic Peptides Compared (BDNF vs GABA)

Semax and Selank are the two best-known peptides to emerge from Soviet and Russian neuropeptide research programs, and they are constantly mentioned in the same breath. Both are short, synthetic peptides built by taking a naturally occurring sequence and bolting on a Pro-Gly-Pro tail to slow enzymatic breakdown. Both have been studied for cognition, stress, and neuroprotection in laboratory and animal models. But mechanistically they pull in different directions: Semax is the focus-and-neuroprotection peptide associated with BDNF and dopaminergic signaling, while Selank is the calm-and-anxiolytic peptide associated with GABA and serotonin modulation. This article compares the two strictly as research compounds. Everything here is research use only, not for human consumption, and we describe preclinical findings rather than any human protocol.

Two Russian Research Peptides, Two Different Goals

Both peptides trace back to the same scientific lineage. Semax was developed from work on adrenocorticotropic hormone (ACTH) fragments, and Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a stabilized analog of the immune peptide tuftsin. In Russia, both have been registered as pharmaceutical products, which is why the research literature on them is unusually deep for compounds that remain unapproved in the United States. That shared origin is where the similarity largely ends. The most useful mental model is a split along a single axis: Semax is studied as a stimulating, focus-oriented, neuroprotective peptide, and Selank is studied as a calming, anxiolytic peptide. The rest of this comparison unpacks why that framing holds up against the mechanistic literature.

Semax: ACTH(4-10) Origin and BDNF Upregulation

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment of adrenocorticotropic hormone, with a Pro-Gly-Pro tail added for metabolic stability. Importantly, although it is derived from ACTH, the ACTH(4-10) portion has essentially no affinity for the melanocortin-2 receptor, so in research models it does not drive cortisol release the way the parent hormone does. Instead its signature is neurotrophic.

In a frequently cited study, Dolotov and colleagues reported that a single intranasal application of Semax in rats produced roughly a 1.4-fold increase in BDNF protein, a 1.6-fold increase in TrkB receptor phosphorylation, and a roughly 3-fold increase in BDNF mRNA in the hippocampus (Dolotov et al., Brain Research, 2006). The authors linked these changes to the hippocampal BDNF/TrkB system that underlies learning and memory in their model. Later ischemia work found that Semax and its Pro-Gly-Pro metabolite activate transcription of neurotrophins and their receptors after cerebral ischemia (Semax and Pro-Gly-Pro, PMC), and reviews note upregulation of vascular endothelial growth factor (VEGF) alongside BDNF and NGF.

On the neurotransmitter side, Semax has been described as activating dopaminergic and serotoninergic systems in rodents. In one study, Semax alone did not change baseline striatal dopamine, but it markedly potentiated the dopamine and locomotor response to amphetamine, while raising the serotonin metabolite 5-HIAA (Eremin et al., Neurochemical Research, 2005). This is the basis for describing Semax as having dopaminergic, focus-leaning activity rather than direct stimulant action. You can review COA and lot data for our research material on the Semax product page and confirm batch testing on the verify page.

Selank: Tuftsin Analog and GABA/Serotonin Modulation

Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a synthetic analog of tuftsin, an endogenous immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) derived from the heavy chain of immunoglobulin G. As with Semax, a Pro-Gly-Pro extension was added to the C-terminus to improve stability against peptidases. Because it grows out of an immune peptide, Selank retains immunomodulatory properties in research models, including effects on interleukin-6 and T-helper cytokine balance, which distinguishes it from purely neuro-active nootropics.

Selank's most studied behavioral signature is anxiolytic. In animal models it has shown anti-anxiety, anti-stress, and antidepressant-like effects, and Russian clinical research has compared its anxiolytic profile to benzodiazepines, but without the classic sedation and dependence profile, because Selank does not appear to bind GABA-A receptors directly. Instead, mechanistic work points to modulation of the GABAergic system at the gene-expression level. A Frontiers in Pharmacology study found that Selank altered the expression of genes involved in GABAergic neurotransmission in the rat frontal cortex, with changes correlated to those produced by GABA itself (Volkova et al., Front. Pharmacol., 2016). A follow-up in IMR-32 cells reported similar effects on GABAergic gene expression in vitro (Kolomin et al., Front. Pharmacol., 2017).

Selank also modulates serotonin and other monoamines: animal studies report that it influences serotonin metabolism and monoamine concentrations, and it has been reported to affect BDNF expression and enkephalin metabolism as well. So while Selank touches BDNF too, its dominant identity in the literature is GABA/serotonin-linked calm, not the dopaminergic, neurotrophic focus profile of Semax.

Focus vs Calm: The Core Distinction

If you reduce the two peptides to a single contrast, it is this: Semax = focus and neuroprotection; Selank = calm and anxiolysis. Semax leans on BDNF/NGF/VEGF upregulation plus dopaminergic and serotonergic activation, which researchers associate with attention, learning, and cognitive performance under stress. Selank leans on GABAergic gene modulation plus serotonergic effects, which researchers associate with reduced anxiety-like and stress behaviors. This focus-versus-calm dichotomy is the dominant framing across the literature and is the most reliable way to keep the two straight.

• Semax — ACTH(4-10)-derived; BDNF, NGF, VEGF upregulation; dopaminergic/serotonergic activation; studied for focus, learning, and neuroprotection.
• Selank — tuftsin-derived; GABAergic and serotonergic modulation; immunomodulatory; studied for anxiolytic and anti-stress effects.
• Both add a Pro-Gly-Pro tail for stability; both come from Russian peptide-research programs; both are studied intranasally in animal models.

Neuroprotection and Stress-Research Contexts

The two peptides overlap most in the neuroprotection and stress literature, which is part of why they are studied together. Semax has been investigated in models of cerebral ischemia and MPTP-induced dopaminergic lesions, where its neuroprotective activity is attributed to a combination of neurotrophin upregulation and modulation of the dopaminergic system. Selank, coming from the anxiolytic side, is studied in stress and anxiety paradigms, where its GABAergic and immunomodulatory actions are the focus. In other words, Semax is the neuroprotection-and-cognition workhorse and Selank is the anxiety-and-stress workhorse, but both touch the shared theme of protecting the brain under adverse conditions. None of this constitutes evidence of human therapeutic benefit; these are preclinical and animal-model observations, and Russian regulatory registration does not equate to US approval.

Why Researchers Study Them Together

Because their mechanisms are largely complementary rather than redundant, Semax and Selank are frequently examined as a pair in nootropic-peptide research. The conceptual appeal is straightforward: one peptide is associated with upregulating drive, focus, and neurotrophic signaling, while the other is associated with damping anxiety and stress reactivity. Investigators interested in the broader question of how short peptides modulate cognition and mood often characterize both in parallel to map the focus axis against the calm axis. That pairing is a research design choice, not a recommendation for combined human use. If you are exploring related compounds, our peptide research catalog and other learn articles cover neighboring molecules, and every lot we stock is third-party HPLC tested with a COA you can confirm on the verify page.

Comparison Table

• Sequence — Semax: Met-Glu-His-Phe-Pro-Gly-Pro | Selank: Thr-Lys-Pro-Arg-Pro-Gly-Pro
• Parent molecule — Semax: ACTH(4-10) fragment | Selank: tuftsin (IgG-derived immune peptide)
• Primary mechanism — Semax: BDNF/NGF/VEGF upregulation, dopaminergic + serotonergic activation | Selank: GABAergic gene modulation + serotonergic, immunomodulatory
• Dominant research framing — Semax: focus, cognition, neuroprotection | Selank: calm, anxiolytic, anti-stress
• Receptor binding note — Semax: negligible MC2R affinity (no cortisol drive) | Selank: does not directly bind GABA-A receptors
• Origin — Both: Russian peptide-research programs; both registered as drugs in Russia, neither US-approved
• Status — Both: research use only, not for human consumption

Research Use Only

Semax and Selank are unapproved in the United States and are offered strictly as research compounds for laboratory and in-vitro investigation by qualified researchers. The findings summarized here come from animal and cell-based studies plus Russian clinical literature; they are not evidence of safety or efficacy in humans and must not be read as dosing guidance or medical claims. SoCal Labs 1776 supplies lot-tracked, third-party HPLC-tested material with a published certificate of analysis for each batch, which you can review on the verify page. Handle, store, and dispose of all research peptides in accordance with applicable laws and institutional guidelines.